Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells
These findings suggest that targeting tyrosinase could convert cold tumors into an immune-responsive state in vivo using murine models. Inhibiting tyrosinase could enhance the effectiveness of PD-1 blockade, offering a new approach for melanoma patients who fail in current PD-1 inhibitor treatment.
Authors
- Kan He (ORCID: https://orcid.org/0000-0002-3385-7129)
- Yinming Liang (ORCID: https://orcid.org/0000-0001-9174-4037)
- Haipeng Teng (ORCID: https://orcid.org/0000-0003-2987-7415)
- Toby Lawrence (ORCID: https://orcid.org/0000-0003-0967-6122)
- Tianhan Li
- Marc Bajénoff (ORCID: https://orcid.org/0000-0002-0702-8319)
- Liaoxun Lu (ORCID: https://orcid.org/0000-0002-5342-2720)
- Yingzhuo Shen
- Xinyu Feng (ORCID: https://orcid.org/0000-0002-4120-7759)
- Rong Huang (ORCID: https://orcid.org/0000-0003-0215-4823)
- Binhui Zhou (ORCID: https://orcid.org/0000-0001-5970-3665)
- Lichen Zhang (ORCID: https://orcid.org/0000-0002-7810-9941)
- Guo Guo (ORCID: https://orcid.org/0000-0002-4407-2060)
- Mengjun Xu (ORCID: https://orcid.org/0009-0002-7239-5948)
- Yingbin Wang
Institutions
- King's College London (GB)
- Henan Medical University (CN)
Publication Details
- Journal
- BMC Biology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1186/s12915-025-02237-4
- Citations
- 5
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 3.99
Funders
- National Natural Science Foundation of China